Seeking Alpha

Eli Lilly lung-cancer drug meets goal of Phase III study

  • Eli Lilly's (LLY +4%) Ramucirumab met the main goal of a Phase III study of patients with second-line non-small cell lung cancer (NSCLC) by improving survival rates compared with a placebo.
  • Ramucirumab and the placebo were administered in combination with the chemotherapy Docetaxel.
  • Ramucirumab also showed a statistically significant improvement in progression-free survival. (PR)
Comments (2)
  • Momintn
    , contributor
    Comments (3845) | Send Message
    The progression-free survival was less than 2 months in gastric cancer. What is it for this treatment in lung cancer?
    19 Feb, 09:13 AM Reply Like
  • Running Loose
    , contributor
    Comments (15) | Send Message
    Very good point , need to be very astute with them.
    20 Feb, 11:09 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: